I have high positive expectations for news coming at the Ligand presentation tomorrow afternoon.
If Viking continues to improve its market cap, doesn't it seem logical that Ligand will revise its holdings in a positive way? I say this because they previously wrote off a significant amount of their investment. (I don't believe this will have a significant impact, but I believe in consistency.)
SLNO (MC $26 M) BLOCKBUSTER in Phase 3 /Rare Disease +Orphan Status /$2+ BILLION Market /NO Debt = REAL Unknown low float stock with 1000% upside Potential and more .Next billion dollar rare disease company like SRPT here .GLTA
Soleno therapeutics (SLNO)
Market Cap $26 Million Cash: $8 Million Price $0.54
Shares Out: 47.6 Million ( 36 Million shares held by Insiders & Institutions)
•Company expects to initiate pivotal Phase III clinical trial by year-end 2017; will take approximately 9-12 months to complete
Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017.
Market Opportunity for PWS is Substantial.
While the lack of approved treatments for PWS alone make it difficult to assess the market, sales of Pfizer’s (NYSE: PFE) Genotrop in (somatropin) can provide some insight despite being indicate for PWS, in addition to, growth failure due to growth hormone deficiency(GHD),Turner syndrome,idiopathic short stature,and small for gestational age.This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population. To assess the potential of DCCR for PWS, we performed a scenario analysis, which indicates that annual sales could be in the range of $1.1 billion given a moderate price point and 50% market penetrance.
LGD-6972 PII data:
1. Robust safety and efficacy with clinically meaningful decrease in A1C, good dose response in the range of 5-15 mg, and excellent tolerability/safety profile. 2. GRA mechanism targeted by LGD-6972 is active both in Type 1 and Type 2 diabetes, opening up a substantial market for this diabetes drug. 3. LGND will get a solid partnership for LGD-6972 if it decides to partner after this PII, but still has the option to run the PIII on its own and then partner on favorable terms such as 50/50 split of revenues.
LDG-6972 will make a significant contribution to the growth of LGND market cap going forward.
LGND partner AMGN claims Kyprolis should be standard of care for multiple myeloma:
Data shows Kyprolis should be ‘standard of care’, claims Amgen
The US Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) based on data demonstrating that Kyprolis (carfilzo
A 1% decrease in A1C is clinically significant and that P value is very convincing. In my cursory review of clinical results for SGLT2 inhibitor INVOKANA, this impact on A1C is comparable to that blockbuster drug, depending on the starting A1C level.
We don't know the relative variation in response and whether the impact is more or less in different sub-populations...yet.
SGLT inhibition is a different mechanism with a different profile of health benefits and risks.
They state they will pursue this for Type I and Type II diabetes...no approved drugs for Type I diabetics. Look for partnering announcements soon and short interest to vaporize.
We just got amazing news on Diabetes. Next VKTX, buy that now, it will be 5.00 in a hurry in 4th quarter. Disclosure, I have 25,000 shares of VKTX at 1.14 average.
Sage Therapeutics' stock sinks after disappointing late-stage trial of SRSE treatment
LGND looks decent today but latley it has been like watching paint dry. For some decent trade tips check out thestock-dork now .
Why don't we hear from Duche bank, you know, the ones who called 110, and we watched it drop lower than than. I bet ya dollars to donuts, that Duche band bot a crud load of shares after the downgrade, they just reached into Grannies purse and stole, not me.
LGND partner ImmunoPrecise announces successful development of fully human Ab's using OmniAb platform:
ImmunoPrecise Announces R&D Success Using The OmniAB® Platform to Develop Fully Human Antibodies - ImmunoPrecise Antibodies LTD
Victoria, British Columbia, Canada, August 29, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE:[...]
MARK MY WORDS, I HAVE OWNED THIS SINCE THE REVERSE SPLINT AT 7.50. AMAZING RUN, AMAZING COMPANY, AMAZING MANAGEMENT. THIS PUPPY, AGAIN, MARK MY WORDS, AS STILL SOMEWHAT UNAPPRECATED AND UNDISCOVED AND MISUNDERSTOOD, WILL BE 250 NEXT YEAR WHEN MORE INVESTORS APPRECIATE THIS MAGNIFICENT STORY.
LGND partner ARMO BioSciences raises $67 to develop OmniAb based IO therapeutics:
ARMO BioSciences Raises $67 Million in a Series C-1 Financing
REDWOOD CITY, Calif., Aug. 29, 2017 /PRNewswire/ -- ARMO BioSciences, Inc., a late-stage immuno-oncology company,...
Diabetes 2 drug should be worth a lot of money by Ligand standards. Any thoughts on when the deal will be done?
weak as can be, some new won't even help, when wall street decides to poop on you, it poop's on you... Damn thing will be 140 by end of the year, the banks want in and are driving down, way institutonally held..